Nanoparticles comprising peptides including an n-terminal linker

A pharmaceutical composition comprising:

• a. a first peptide comprising an amino acid sequence of RRQLQPFPQPELPYPQPE;
• b. a second peptide comprising an amino acid sequence of RRQQPFPQPEQPFPWQP;
• and
• c. a third peptide comprising an amino acid sequence of RRLPEQPIPEQPQPYPQ;
• wherein the first, second, and third peptides are each associated with a nanoparticle, and wherein the amino acid sequence of the first, second, and third peptides each comprise an N-terminal linker sequence comprising at least one Arg amino acid residue.

A method of treating celiac disease, or inducing tolerance to celiac disease antigens, comprising:

• a. administering a first peptide comprising an amino acid sequence of RRQLQPFPQPELPYPQPE;
• b. administering a second peptide comprising an amino acid sequence of RRQQPFPQPEQPFPWQP;
• and
• c. administering a third peptide comprising an amino acid sequence of RRLPEQPIPEQPQPYPQ;
• wherein the first, second, and third peptides are each associated with a nanoparticle, and wherein the amino acid sequence of the first, second, and third peptides each comprise an N-terminal linker sequence comprising at least one Arg amino acid residue.

The method of claim 48, comprising:

• a. administering a first type of nanoparticles each associated with the first peptide;
• and
• b. administering a second type of nanoparticles each associated with the second peptide;
• and
• c. administering a third type of nanoparticles each associated with the third peptide;
• wherein each of the first type of nanoparticles, the second type of nanoparticles, and the third type of nanoparticles comprises an amphiphilic polymer with a Mn of from 6,000 g/mol to 1,000 g/mol, and wherein the amphiphilic polymer is selected from the group consisting of poly(maleic acid-1-octadecene), poly(maleic acid-1-tetradecene) and poly(maleic acid-1-dodecene).